04 Nov 2021

UK becomes first to authorize Merck and Ridgeback Biotherapeutics’ antiviral molnupiravir to treat mild-to-moderate Covid-19

The Merck and Ridgeback Biotherapeutics’ oral antiviral, molnupiravir, was authorized by the UK Medicines and Healthcare Products Regulatory Agency on Thursday for treatment of mild and moderate Covid-19 cases. This is the first antiviral oral drug to be authorized for the treatment of Covid-19 and is authorized for adults at

Read More